|
The
Market Edge Market Summary
http://www.marketedge.com/
Soothing
comments from Fed Chairman Bernanke concerning inflation worries fueled
stocks last week as several of the major indexes posted record highs.
The DJIA, which had been languishing in the 12500 - 12600 area for over
a month perked up on Tuesday gaining 102 points. It added another 87 on
Wednesday to close above 12700 for the first time in history (DJIA
12741.86). Thursday saw some minor follow through as did Friday despite
a lousy housing start report which showed that new home construction had
plunged to a ten year low. For the period, the DJIA gained 185 points
(+1.4%) closing at 12767. The
NASDAQ, which had been down for three of the last four weeks, found some
footing as it made a run at 2500, a level not seen since 01/12/07
(NASDAQ – 2502.82). For the period the NASDAQ gained 36 points (+1.4%)
and closed at 2496.
Navarro's
Big Economic Picture
Congressional
Counterattack
So
back I went to D.C. last week in the middle of a snow storm and a
nightmarish Jet Blue flight home that stretched almost 24 hours.
Still, it was worth it. The
hearing I testified at was before the House Ways and Means Trade
Subcommittee, and my fellow witnesses were very interesting to listen
to. Lots of “war stories”
from the front line of Chinese mercantilism – and the devastation it
is causing in American industry. In
addition, Congressman Sandy Levin (D-MI) looks serious about introducing
a series of bills that may finally begin to fight back against China’s
ubiquitous unfair trade practices.
My
value-added in the hearing was to provide a comprehensive accounting of
the various sources of China’s competitive advantage and to illustrate
how much of this advantage is linked to direct, indirect, or hidden
subsidies.
The
full testimony is tacked on to the end of the newsletter after the ETF nightlights
as I don’t want to step on Andrew Vaino’s fine column this week.
You can read the testimony of the other participants at http://waysandmeans.house.gov/hearings.asp?formmode=detail&hearing=525
I particularly recommend
that of Goodish, Vargo, Bassett, and Tyrone.
This
Week's Market Movers
The
CPI and FOMC minutes promise to be the highlight of an otherwise light
week on the macro calendar. With
the CPI, it’s always about any nasty upside surprise.
The
International Scene - Technical Take
There
was some subtle but arguably strong improvement in the global economy.
The big mover was South
Korea (EWY), moving to a solid “buy” with a double top breakout.
We also saw firming in Europe, Asia and Latin America.
The planet remains bullish… SEE
BELOW
|
Country
or Region
|
ETF
|
This
Week
|
Two
Weeks Ago
|
|
U.S.
|
SPY
|
Long,
-1
|
Long,
-2
|
|
U.S.
|
QQQQ
|
Avoid
|
|
|
Europe
|
EZU
|
Long,
-1
|
Long,
-2
|
|
Europe
S&P Eur 350
|
IEV
|
Long,
0
|
Long,
-2
|
|
- Germany
|
EWG
|
Long,
0
|
Long,
-1
|
|
Emerging
Markets*
|
EEM
|
Long,
-1
|
Long,
-2
|
|
Asia
50 ADR
|
ADRA
|
Long,
-1
|
Long,
-1
|
|
- China 25
|
FXI
|
Long,
-2
|
Long,
-2
|
|
- Japan
|
EWJ
|
Long,
0
|
Long,
0
|
|
- Australia
|
EWA
|
Long,
0
|
Neutral
from Long, -2
|
|
- Korea
|
EWY
|
Long,
0
|
Avoid,
1
|
|
Latin
America
|
ILF
|
Long,
0
|
Long,
0
|
|
- Brazil
|
EWZ
|
Long,
-0
|
Long,
-0
|
|
- Mexico
|
EWW
|
Long,
0
|
Long,
-1
|
|
India
|
IFN
|
Avoid
|
--
|
|
Gold
|
GLD
|
Long,
0
|
Neutral
from Long, -1
|
*Argentina,
Brazil, Chile, China, Colombia, Czech Republic, Egypt, Hungary, India,
Indonesia, Israel, Jordan, Korea, Malaysia, Mexico, Morocco, Pakistan,
Peru, Philippines, Poland, Russia, South Africa, Taiwan, Thailand, and
Turkey.
Testimony
of Business Professor Peter Navarro
before the House Ways and Means Trade Subcommittee
February 15, 2007
Mr.
Chairman and members of the Subcommittee.
My name is Peter Navarro, and I want to thank the members and
staff of this subcommittee for the opportunity to testify today on the
crucial issue of U.S.-China trade relations – specifically the role of
a complex web of mercantilist export subsidies in providing China with
an unfair competitive advantage over U.S. manufacturers.
As
a biographical note, I am a business professor at the University of
California-Irvine and hold a PhD in economics from Harvard University.
My research has appeared in academic journals ranging from the
Journal of Economic Perspectives, the Journal of Business, and the Rand
Journal to the Harvard Business Review and China Perspectives.
I am also the author of a number of books on economics and public
policy, including The Coming China Wars: Where They Will Be Fought,
How They Can Be Won (Financial Times, 2006).
My
value-added in this proceeding will be to provide members with a
conceptual framework with which to understand the broad scope of Chinese
mercantilist practices as well as to provide a more expansive definition
of what constitutes an unfair “mercantilist export subsidy.”
In
this testimony, I will identify the eight major drivers of the so-called
“China Price,” which is a short hand term for Chinese competitive
advantage in world markets. Most
importantly, I will illustrate how fully 7 of these 8 China Price
drivers are, in turn, driven by a complex web of direct, indirect, and
hidden mercantilist export subsidies.
I
shall conclude this testimony by urging Congressional policymakers not
to compartmentalize the various factors contributing to China’s unfair
trade practices nor deal with them in piecemeal policy fashion.
Instead, I urge Congressional
leaders to address Chinese mercantilism in a comprehensive and
integrated fashion that hits all mercantilist points of the China Price
compass. The framework
offered in this testimony may be helpful in the policy architecture and
design.
China’s
Clear and Present Danger to America
By
practicing a highly evolved form of 18th century “beggar
thy neighbor” mercantilism, China is emerging as a 21st
century economic
superpower. While
consumers around the world have benefited from the flood of cheap goods,
China’s broad portfolio of unfair trade practices has resulted in the
loss of millions of jobs in countries ranging from the United States and
Mexico to Brazil and Lesotho. Chinese
mercantilism is also depressing wage and income levels worldwide while
China’s exploitation of lax environmental and health and safety
standards as competitive drivers is killing millions of Chinese workers
and citizens and generating significant regional and global pollution.
To
understand both the breadth and depth of Chinese mercantilism and its
far ranging effects, it is essential to first understand the
mercantilist roots of the so-called “China Price” and the complex
web of direct, indirect, and hidden export subsidies that have so
sharply honed China’ global competitive advantage.
The China Price refers to the ability of Chinese manufacturers to
undercut global competitors by as much as 50% or more over a wide range
of manufactured goods. Today,
as a result of this powerful “weapon of mass production,” China has
emerged as the world’s blue collar “factory floor.”
The
rapidity with which China has captured a wide range of markets is
breathtaking: Already, China controls over 70% of the world’s market
share for DVDs and toys, more than half of the share for bikes, cameras,
shoes, and telephones; and more than a third for air conditioners, color
TVs, computer monitors, luggage, and microwave ovens.
It has established dominant market positions in everything from
furniture, refrigerators and washing machines to jeans and underwear
(yes, boxers and briefs). As
it moves inexorably up the value chain, China is now even making rapid
inroads into the global auto market.
In
wielding the China Price to capture these markets, China has all but
gutted many segments of blue collar manufacturing in countries around
the world. In this regard,
it’s one thing for America to lose much of its blue collar
manufacturing base to China. If
the U.S. loses its white collar science and technology base too, it will
be Americans living the peasant life rather than the Chinese.
Alarmingly,
under the catalyst of Chinese mercantilism, the shift of America’s
white collar science base has already begun.
For example, the American biotech and pharmaceutical industries
are already well on their way to offshoring much of their research and
development and production to China.
Indeed, today, there are more than 300 biotech companies in
China, and nearly every major pharmaceutical company has built, or is
building, a research center in China.
An
Expanded Definition of “Export Subsidy”
Given
current trends, it is crucial that U.S. policy makers cultivate a much
more sophisticated understanding of the phenomenon of the China Price
– as well as its mercantilist foundation and roots.
In cultivating this understanding, it is equally essential for
U.S. policymakers to use a broad definition of what truly constitutes an
unfair “mercantilist export subsidy.”
The clear danger of using an overly narrow definition is that
policymakers will compartmentalize various aspects of Chinese
mercantilism, e.g., currency manipulation, IP protection, and then
attempt to deal with these issues legislatively in a piecemeal fashion.
In
this regard, while there are various legal and technical definitions for
what constitutes an illegal or prohibited export subsidy in forums like
the GATT and the WTO, the most useful economic definition for
policymaking purposes is an expansive definition of a mercantilist
export subsidy that includes any direct or indirect government action
or inaction that unfairly stimulates export activity at the expense of
trading partners.
For
example, a direct government action would be the use of tax rebates for
exporters while an indirect action would be currency manipulation, which
is designed to undervalue a country’s exchange rate and thereby gain
competitive advantage. More
subtly, a government inaction would be the sanctioning of
counterfeiting and piracy despite laws established to prevent such
practices. Each of these
direct and indirect government actions and inactions may be thought of
most broadly as “mercantilist export subsidies” because their intent
is to encourage the country’s export trade in ways which are clearly
outside the bounds of free and fair trade.
The
table on the next page provides an overview of the eight major drivers
of the China Price and the various direct, indirect, or hidden
mercantilist export subsidies used by China to capture markets in world
trade. This table is based
on a research project I conducted with a large team of MBA students over
a year long period at the University of California-Irvine
(Download The Report of the China Price Project at www.peternavarro.com
). The purpose of that
project was to answer these two questions: What are the major sources of
Chinese competitive advantage in world markets and to what extent is
Chinese competitiveness driven by fair versus unfair trading practices.
Column
One of the table on the next page identifies the various “Pure
Mercantilism” and “Mixed Mercantilism” drivers of the China Price
while Column Two indicates their relative importance in the China Price
equation. The third
column may be of most interest to this subcommittee.
It identifies the array of mercantilist export subsidies
associated with each China Price driver.

The
first five China Price drivers represent a very pure form of Chinese
mercantilism and account for over 40% of China’s competitive
advantage. These drivers
include a pervasive system of subsidies and tax preferences designed to
stimulate the export economy, currency manipulation which distorts the
dollar-yuan exchange rate relative to market forces,
government-sanctioned counterfeiting and piracy, and a set of lax, and
laxly enforced, environmental and health and safety regulations that
fall far short of international norms and standards.
The
sixth and seventh Chinese Price drivers are Foreign Direct Investment
and Low Labor Costs. These
drivers may be characterized as “Mixed Mercantilism” because of
various mercantilist elements which enhance what would otherwise be a
fair comparative advantage. (The
final driver, not pictured in the table, is a very sophisticated form of
industrial network clustering. See
Report of the China Price Project for details, www.peternavarro.com
.)
China
Price Driver #1: Subsidies, Tax Preferences, and Other WTO Violations
Under
state control, many Chinese state-owned manufacturers are operating with
the benefit of state-sponsored subsidies, including: rent, utilities,
raw materials, transportation, and telecommunications services.
That is not how we define a level playing field.
- Former U.S. Department of
Commerce Secretary Donald Evans
The
first China Price driver encompasses a wide, but often difficult to
detect, array of mercantilist subsidies and tax preferences that provide
Chinese exporters with reduced costs. This
array includes subsidized energy and water as well as preferential
access to free or cheap land or rent.
Despite
alleged reforms, China’s state-owned banks also continue to hold a
large portfolio of non-performing loans.
These NPLs often have been issued in a preferential manner and
without expectation of repayment, providing many Chinese enterprises
with essentially free money. Despite
numerous WTO-related complaints, China also continues to use an
extensive tax rebate system for its export industries.
China
Price Driver #2: Currency Manipulation
To
maintain its undervalued currency – and thereby sell it exports cheap
and keep foreign imports dear – China maintains a fixed currency peg
between the U.S. dollar and the yuan. To
maintain that peg, China must recycle large sums of its surplus U.S.
dollars gained in the export trade back into the U.S. bond market.
Through such activity, China has become the de facto “central
banker” of the U.S., with its net capital inflows roughly equal to
that needed to finance the U.S. budget deficit.
Chinese
currency manipulation is an indirect export subsidy because it
artificially depresses the price of Chinese exports while inflating the
price of exports from the U.S. This
is not the only effect of Chinese currency manipulation, however.
More
subtly, China’s massive recycling of its surplus U.S. dollars back
into the U.S. bond market has helped keep long term interest rates and
mortgage rates artificially low. This,
in turn, has helped transform the typical U.S. home into an “ATM
machine.” Indeed, many
Americans have become “serial refinancers” of their homes.
By taking equity out of their homes, they have managed to boost
their consumption in the short run, and much of what these serial
refinancers spend is on cheap Chinese imports.
The practical effect has been a short run boost to the economy.
Longer term, this is a dangerous situation because it is saddling
U.S. consumers with more and more debt and U.S. homeowners with more and
more risk of defaulting on their mortgages.
China
Price Driver #3: Counterfeiting and Piracy
China
is the piracy capital of the world. It
accounts for 2/3ds of all the world’s pirated and counterfeited goods
and fully 80% of all counterfeit goods seized at US borders.
Chinese
counterfeiting and piracy help lower production costs for Chinese
manufacturers relative to competitors in a number of ways that vary in
degree by industry. For example,
Chinese counterfeiters don’t have to pay for R&D costs.
This has been a particular stimulant to sectors like autos and
pharmaceuticals. Nor do
Chinese pirates who steal software have to pay for IT costs while
Chinese counterfeiters save on marketing costs because they don’t have
to build brand.
Chinese
counterfeiting and piracy is a classic example of how government inaction
leads to a mercantilist export subsidy. Despite
highly publicized periodic crackdowns on counterfeiting and piracy by
the Chinese government, much of it remains state-sanctioned.
Indeed, stripped of Chinese rhetoric, counterfeiting and piracy
represent a cornerstone of the country’s discretionary macroeconomic
policies.
In
this regard, it has been estimated that anywhere from 20% to as much as
a third of China’s GDP is derived from counterfeit and pirate
activity. This intellectual
property theft generates tens of millions of jobs while keeping prices
and inflation low. That’s
why, absent outside pressure from the U.S. and other members of the
global community, China will continue to merely give lip service to IP
protection.
China
Price Driver #4: Lax Health and Safety Standards
Lax
health and safety standards represent an important hidden mercantilist
export subsidy. Under China's lax
regulatory regime, China has become one of the most dangerous places to
work in the world.
The
highest risk industries in China include building materials, chemicals,
coal production, machinery manufacture, metallurgy, plastics, and
textiles. Diseases ranging from silicosis and brown lung to a variety of
cancers caused by the ingestion, inhalation, or contact with toxic
chemicals and waste are endemic. Workplace
injuries are endemic.
The
cost advantages to Chinese exporters derived from this lax health and
safety regime range from the use of cheaper equipment for workers and
fewer safety-related expenses to savings on training and safety-related
large capital expenditures. For
example, Chinese textile companies are unlikely to invest in anti-noise
or dust control equipment. Chinese coal mining companies tend to skimp
on masks, goggles, and emergency rescue facilities while a wet drilling
system costs as much as 60% more than a dry drilling system but
significantly reduces hazardous dust emissions.
In
addition, the compensation of Chinese workers who are maimed or
dismembered in the production process is often reduced or withheld by
companies in China. This callous
behavior results in a reduction in liability costs for Chinese exporters
relative to global competitors.
China
Price Driver #5: Lax Environmental Standards and Enforcement
China’s
lax environmental regulations and weak enforcement likewise provide
Chinese exporters with a hidden mercantilist export subsidy.
There is, however, some irony in using the term “hidden”
here. China’s air and
water pollution are highly visible within China – with Beijing,
Shanghai, and China’s industrial heartland often enveloped in a toxic
shroud. Meanwhile, America’s
air basins are also being despoiled by Chinese “chog,” an equally
toxic combination of smog, particulate and hazardous substances like
mercury, while much of the acid rain falling in both Japan and South
Korea is “made in China.
China
lax environmental regime provides a variety of cost advantages to its
industrial sector. Enterprises
save money on protective equipment for workers.
Many don’t have to invest in pollution control technologies
while those that do invest save money by not operating the equipment.
Waste disposal costs are also considerably reduced.
The net result is a significant reduction in compliance costs
relative to competitors.
China
Price Driver #6: Foreign Direct Investment
Among
developing nations, China has become the leading destination of Foreign
Direct Investment (FDI). Since
1983, FDI has grown from less than $1 billion a year to over $60
billion. 72% of China’s FDI
targets manufacturing.
This
China Price driver fits into the category of “Mixed Mercantilism.”
This is because that while much of FDI is attracted to China because of
China’s comparative advantage in labor and the promise of a burgeoning
new market, FDI is also arriving on China’s shores because of various
mercantilist aspects of the Chinese economy.
For
example, both the aforementioned lax health and safety standards and
weak environmental laws and enforcement have helped attract FDI from
countries like Japan, South Korea, Taiwan, and the U.S. where standards
are much higher. This observation
illustrates an undesirable synergy between China’s mercantilist
policies and the attraction of FDI.
Equally
troubling is the pervasive practice of the “round tripping” of
Chinese capital. In
particular, 20% to 30% of China’s FDI is estimated to be of domestic
origin. It is the result of the
“round tripping” of mainland Chinese capital, primarily through Hong
Kong (and also the Virgin Islands). This
round tripping of capital is clearly mercantilist in nature and quite
contrary to the spirit and tenets of the WTO. This is because it is
driven by the special preferences awarded to FDI in the form of lower
tax rates, land use rights and subsidies, administrative support, and
other subsidies as well as by a desire to evade foreign exchange
controls.
China’s
catalytic FDI provides a variety of competitive benefits.
It finances the transfer of the most technologically advanced
production and process technologies. It
has brought with it managerial best practices and skills as many FDI-financed
enterprises are managed by foreign talent.
FDI is also often tied to the improvement of both marketing and
distribution skills. When all of
these attributes are tied to one of the least expensive labor forces in
the world, FDI becomes a powerful competitive driver.
To the extent that a significant component of FDI is driven by
mercantilist elements, it represents a hidden mercantilist export
subsidy.
China
Price Driver #7: Low Labor Costs
The
China Price driver of low labor costs likewise fits into the category of
“Mixed Mercantilism.” While
China has an undeniable comparative advantage in its well-disciplined
and well-educated workforce, China’s low wage costs are also driven by
significant mercantilist elements.
The
aforementioned lax health and safety standards represent one such
element. In addition, there are
the well-known problems of the use of slave labor, the specification of
labor contracts in a manner which constitutes indentured servitude, the
failure to pay the minimum wages specified under law, and the lack of
any right to freely associate or organize into bargaining units or
unions. Together, Chinese
mercantilism in the workplace provides Chinese exporters with an
additional unfair advantage over competitors.
Summary
and Conclusions
The
picture that emerges from this analysis of the China Price and its
economic drivers is that of a
picture of a country singularly intent on export-driven growth that uses
a complex web of direct, indirect, and hidden mercantilist export
subsidies to beggar its neighbors. The
policy framework strongly suggested by this China Price-Mercantilist
Export Subsidy analysis is one that requires a comprehensive, rather
than piecemeal, policy approach.
In
particular, rather than deal with each of the various aspects of Chinese
mercantilism such as IP protection or currency manipulation or labor
abuses with separate pieces of legislation, it may be far more useful to
develop an comprehensive, omnibus bill that hits all points of the
mercantilist China Price compass. It
is to this goal that I urge this subcommittee to direct all possible
energies.

Vaino's Biotech
Corner
Biosante!
An
insightful reader emailed me (which I highly encourage!) last fall
suggesting I look further into Biosante (BPA), a small company devoted
to improving drug delivery. This
is an excellent example of a missed opportunity by me, as the stock is
up more than 50% since then.
Biosante
is a tiny (according to their most recent 10-K they have fourteen
employees) company working on transdermal delivery of hormones.
In December of last year, they received FDA approval to market
Elestrin, an estradiol gel designed to be rapidly absorbed through the
skin. It is meant to be applied
daily to the arms, shoulders, abdomen, or thighs. A gel or cream is less
invasive than a patch that needs to be worn continuously.
In
a Phase 3 study Elestrin demonstrated significant decreases in incidence
and severity of hot flashes in menopausal women, but at a substantially
lower dosing level of estradiol. Lower estradiol levels can decrease
undesired side-effects in hormone replacement therapy.
Elestrin will be marketed by Bradley Pharmaceuticals (BDY).
A launch is expected in mid-2007. Bradley Pharmaceuticals has
experience selling specialty pharmaceuticals, so this is a good way to
market their product.
In
addition, Biosante recently announced they had begun a Phase 3 clinical
trial of a similar product, to deliver testosterone, to treat female
sexual dysfunction (FSD). There
is precedent in the scientific literature that administering
testosterone indeed treats FSD. They
also announced positive preclinical results on delivery of a vaccine to
prevent bird flu. While both these products have potential (I’m not
overly impressed by preclinical data), I think the main value-driver of
this company is Elestrin.
As
an aside, there are 493 literature references to clinical trials for FSD
on “Pub Med” (a website that searches the medical literature)
compared to 1,121 for erectile dysfunction in men.
In
an article in “The Motley Fool”, Brian Lawler questioned just how
much of the estrogen market Elestrin will actually capture.
This is a critical issue. Novavax
(NVAX) sells Estrasorb, also a transdermal estradiol delivery system,
and has not gained any real traction in the market.
Novavax
published data from a Phase 3 study in the journal Menopause.
The lowest daily dose of Estrasorb was 8.6 milligrams
of estradiol. By contrast,
according to Phase 3 clinical data, dosing of Elestrin was found to be
effective between 12.5 and 64 micrograms.
For readers less conversant in the metric system, there are 1000 micrograms
in a milligram.
That is, the amount of estradiol dosed with Elestrin is a tiny
fraction of that dosed in Estrasorb. Given
there are known health risks associated with estradiol, the ability to
give a significantly lower dose, I believe, makes for a superior product
that should gain market share.
Current
U.S. estrogen therapy sales are estimated at $1.3B annually.
Transdermal delivery accounts for about $250M, so it’s
definitely a big potential market. According
to the US Census Bureau, total US population
should still hit almost 400M by 2050, and, the median age of that
population will be older. As
estrogen therapies are targeted at 50+ women (also according to the US
Census there are more 50+ women than men) the potential market is
increasing.
Now,
Biosante’s balance sheet is troublesome. As part of their deal with
Bradley there are to receive $10M within the year.
In addition, terms of the deal call for milestone payments and
royalties. Triggers for sale-base
milestones, which can reach $30M, have not been disclosed.
While
I would prefer more transparency in Biosante’s deal with Bradley, I do
think they have a good product in a growing market.
As always, proof will be in the execution and this certainly
is not risk-free. This is
a nanocap stock with a small (<20M shares) float and will be subject
to volatility. While numbers
like $1.3B are pie-in-the-sky, this is a small company.
Even capturing 5-10% of the estrogen replacement market will send
the stock skyrocketing. (Be
careful on the entry, however. The
stock is showing some signs of a retracement.)

“Any
trader or investor who ignores the power of macroeconomics over the
world’s
financial markets will, sooner or later, lose more than they
should—and if they are
trading on margin, perhaps more than they
have.”
-- If It's Raining in Brazil, Buy Starbucks
The
Market Edge Market Summary from www.marketedge.com
|

|
Peter
Navarro is
a business professor at the University of California and the
author of the best-selling investment book
If
It's Raining in Brazil, Buy Starbucks and The
Well-Timed Strategy.
His latest book is The Coming China
Wars: Where They Will Be Fought, How They Can Be Won. |
|

|
Andrew
Vaino is a Ph.D. chemist who spent two years at
The Scripps Research Institute in La Jolla, CA, working in the
laboratories of Nobel-Laureate Barry Sharpless and Kim Janda. He
currently teaches at The University of Maine, where his research
group is focused on exploring the interface between enzymology,
organic chemistry, and nanotechnology. |
©
2007
Peter Navarro and Andrew Vaino
www.peternavarro.com
Editorial Archive
CONTACT
INFORMATION
Peter Navarro
Irvine, California USA
Email
| Website
DISCLAIMER:
This newsletter is written for educational purposes only. By no means do
any of its contents recommend, advocate or urge the buying, selling, or
holding of any financial instrument whatsoever. Trading and investing
involves high levels of risk. The authors express personal opinions and
will not assume any responsibility whatsoever for the actions of the
reader. The authors may or may not have positions in the financial
instruments discussed in this newsletter. Future results can be
dramatically different from the opinions expressed herein. Past
performance does not guarantee future performance.
Disclaimer
|